Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Gastroesophageal Junction Adenocarcinoma: early-phase trial registry
4 of 9 indexed Metastatic Gastroesophageal Junction Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 4 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Metastatic Gastroesophageal Junction Adenocarcinoma: 9 US clinical trials tracked, 4 recruiting.
Metastatic Gastroesophageal Junction Adenocarcinoma is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition metastatic-gastroesophageal-junction-adenocarcinoma
OPEN 4 | RECR 44% | LATE 0 | EARLY 9 | RANK #1916 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)
Metastatic Gastroesophageal Junction Adenocarcinoma lists 4 open slots (44% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Gastroesophageal Junction Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Gastroesophageal Junction Adenocarcinoma is recruiting below its size-band peers.
4 of 9 indexed trials (44.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Metastatic Gastroesophageal Junction Adenocarcinoma research.
National Cancer Institute (NCI) accounts for 3 of 9 trials (33.3%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Metastatic Gastroesophageal Junction Adenocarcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 37 among the 9 trials that report a genuine target (sentinel values excluded). 9 of those (100%) plan for fewer than 100 participants.
-
Metastatic Gastroesophageal Junction Adenocarcinoma research is mostly interventional.
9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
National Cancer Institute (NCI)
NCT06364410
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
Roswell Park Cancer Institute
NCT04511039
Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma
Roswell Park Cancer Institute
NCT05651594
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Memorial Sloan Kettering Cancer Center
NCT06251973
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
NCT01142388
Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer
M.D. Anderson Cancer Center
NCT04220827
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
Academic and Community Cancer Research United
NCT03337087
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
NCT03641313
Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca
Baylor Research Institute
NCT04921904
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Gastroesophageal Junction Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Gastroesophageal Junction Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Gastroesophageal Junction Adenocarcinoma page
9 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Metastatic Gastroesophageal Junction Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Metastatic Gastroesophageal Junction Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Gastroesophageal Junction Adenocarcinoma condition card totals 9 registered trials; most-linked intervention Paclitaxel; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.